|
| Primary information |
|---|
| ID | 10630 |
| Therapeutic ID | Th1128 |
| Protein Name | Velaglucerase alfa |
| Sequence | >Th1128_Velaglucerase_alfa
ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
|
| Molecular Weight | 63000 |
| Chemical Formula | C2532H3850N672O711S16 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | 11-12 Minutes |
| Description | Gene-activated human recombinant glucocerebrosidase. It is used to treat Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. |
| Indication/Disease | Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease. |
| Pharmacodynamics | NA |
| Mechanism of Action | Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight). |
| Clearance | Mean clearance ranges from 6.72 to 7.56 mL/min/kg. |
| Categories | Enzymes |
| Patents Number | US7138262 |
| Date of Issue | 21-11-2006 |
| Date of Expiry | 18-08-2020 |
| Drug Interaction | NA |
| Target | Glucosylceramidase |
| Brand Name | VPRIV |
| Company | Shire |
| Brand Description | Shire |
| Prescribed For | long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease. |
| Chemical Name | NA |
| Formulation | velaglucerase alfa (400 Units), citric acid, monohydrate (5.04 mg), polysorbate 20(0.44 mg), sodium citrate, dihydrate (51.76 mg), sucrose (200 mg) |
| Physical Appearance | VPRIV is supplied as a sterile, preservative free, lyophilized powder |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | The recommended dose is 60 Units/kg administered every other week as a 60-minute Intravenous infusion. |
| Contraindication | NA |
| Side Effects | Headache, Dizziness, Abdominal pain, Nausea, Back pain, Joint pain (knee), Upper respiratory tract infection, Activated partial thromboplastin time prolonged, Infusion-related reaction*, Pyrexia, Asthenia/Fatigue |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |